2024-10-28 09:00:00
Orano Med is evolving its top management. This subsidiary of the nuclear giant Orano, specializing in targeted therapies against cancer using lead-212, a radioactive isotope, has promoted Julien Dodet to the position of chairman of the governance board. He has been general management of the company since 2016.
“This development is recognition of the unique alliance achieved by Orano Med between innovative R&D expertise and world-class production capacities,” explains the management of Orano Med, which intends to position itself as a leader in radiotherapies. vectorized internals. A graduate of the Ecole nationale des Ponts et Chaussées and the Ecole Polytechnique, Julien Dodet worked at Saint-Gobain and BCG before joining Areva in 2011 as head of group strategy, before being appointed CEO of Areva Nuclear Power in China.
Arnaud Lesegretain, general manager
To replace Julien Dodet as general manager of Orano Med, the group selected the profile of Arnaud Lesegretain. Holder of an MBA in management from Harvard Business School and a master’s degree in medical sciences from Harvard Medical School (United States), Arnaud Lesegretain joined the pharmaceutical laboratory Biomérieux in 1993 in positions in finance and information systems.
In 2000, he joined Eli Lilly, where he held various positions in France, Germany and the United States, where he was responsible for oncology treatment. After a stint in 2015-2016 at AstraZeneca in oncology R&D, he retained his specialty by joining the Japanese laboratory Daiichi Sankyo in 2016 in various vice-president positions, based in the United States. He notably participated in the approval of several drugs.
Fabrice Darvey, director of industrial operations
Appointed director of industrial operations at Orano Med, Fabrice Darvey is a graduate of the Ecole Polytechnique and the Ecole des Mines. He began his career in 2007 as an intern then an analyst at Orano, a group that he never left to successively be sales manager then, in the nuclear processing and recycling plant in La Hague (Manche), deputy director and site director for dismantling activity. Since 2021, Fabrice Darvey has been Director of Operational Excellence at Orano. “His background makes him the ideal candidate to accelerate Orano Med’s industrialization efforts and meet global needs for these innovative therapies,” believes the group.
This summer, Sanofi took 15.6% of the capital of Orano Med, in the form of an investment of 300 million euros. A licensing agreement had previously been signed for the marketing rights to AlphaMedix, a treatment developed by Orano Med and the American RadioMedix. In June 2024, Orano Med also inaugurated a laboratory in the United States, a few months after having started the construction of a site in Onnaing, in the North.
1730167667
#Arnaud #Lesegretain #Fabrice #Darvey #Orano #Med #evolving #governance
**Interview with Arnaud Lesegretain, General Manager of Orano Med**
**Editor:** Thank you for joining us, Arnaud. Congratulations on your new role as General Manager of Orano Med. How do you feel about taking on this leadership position within a pioneering company in radiotherapies?
**Arnaud Lesegretain:** Thank you for having me! I’m incredibly honored and excited to step into this role. Orano Med is at the forefront of cancer treatment innovation, and I aim to build on the strong foundation laid by Julien Dodet. My goal is to further enhance our capabilities and ensure we provide effective therapies for patients.
**Editor:** Julien Dodet has been vital in shaping Orano Med’s growth. What aspects of his leadership do you hope to continue or expand upon?
**Arnaud Lesegretain:** Julien’s commitment to integrating R&D with production capabilities has been exceptional. I plan to maintain that focus while emphasizing collaboration across teams. This synergy is essential for launching new therapies and ensuring accessibility for patients who need them most.
**Editor:** Given your impressive background in both finance and medical sciences, how do you plan to leverage your expertise in managing Orano Med?
**Arnaud Lesegretain:** My experience in both fields allows me to approach challenges from multiple perspectives. I aim to foster a culture of innovation while also ensuring we operate efficiently. We need to balance scientific advancements with sound business practices to drive growth and sustainability.
**Editor:** As Orano Med positions itself to become a leader in targeted therapies using lead-212, what challenges do you foresee, and how do you plan to address them?
**Arnaud Lesegretain:** One of the biggest challenges will be navigating regulatory landscapes and ensuring our therapies meet stringent safety and efficacy standards. To address this, we’ll invest in strengthening our regulatory affairs team and forge closer partnerships with health authorities. Continuous dialogue and transparency will be key.
**Editor:** Lastly, what are your immediate priorities in your new role?
**Arnaud Lesegretain:** My immediate priorities include building a strong leadership team, enhancing our research initiatives, and establishing strategic partnerships in the industry. It’s vital that we adapt swiftly to the rapidly changing landscape of cancer therapies and ensure that our innovations successfully translate into effective treatments.
**Editor:** Thank you, Arnaud, for sharing your insights. We look forward to seeing the advancements Orano Med will achieve under your leadership.
**Arnaud Lesegretain:** Thank you! I’m excited for the journey ahead.
**Editor:** Thank you for joining us today, Arnaud. Congratulations on your new role as General Manager of Orano Med. How do you feel about taking on this leadership position within a pioneering company in radiotherapies?
**Arnaud Lesegretain:** Thank you for having me! I’m incredibly honored and excited to step into this role. Orano Med is at the forefront of cancer treatment innovation, and I aim to build on the strong foundation laid by Julien Dodet. My goal is to further enhance our capabilities and ensure we provide effective therapies for patients.
**Editor:** Julien Dodet has been vital in shaping Orano Med’s growth. What aspects of his leadership do you hope to continue or expand upon?
**Arnaud Lesegretain:** Julien’s commitment to integrating R&D with production capabilities has been exceptional. I plan to maintain that focus while emphasizing collaboration across teams. This synergy is essential for launching new therapies and ensuring accessibility for patients who need them most.
**Editor:** Given your impressive background in both finance and medical sciences, how do you plan to leverage your expertise in managing Orano Med?
**Arnaud Lesegretain:** My experience in both fields allows me to approach challenges from multiple perspectives. I aim to foster a culture of innovation while also ensuring we operate efficiently and sustainably. I believe that understanding both the financial and scientific aspects of our work is key to driving growth and achieving our mission of providing cutting-edge cancer therapies.
**Editor:** It’s clear that you’re focused on both innovation and patient care. How important do you think partnerships are, especially considering the recent investment from Sanofi?
**Arnaud Lesegretain:** Partnerships are vital in our industry, especially as we strive to accelerate the development and distribution of our therapies. The investment from Sanofi not only strengthens our financial position but also enhances our reach and capabilities in the market. Collaborating with leading pharmaceutical companies allows us to leverage their expertise and infrastructure, ultimately benefiting the patients who rely on our treatments.
**Editor:** Lastly, what are your immediate goals for Orano Med in the next year?
**Arnaud Lesegretain:** My immediate goal is to ensure a smooth transition following Julien’s leadership while continuing to drive our ongoing projects, especially the launch of new therapies such as AlphaMedix. Additionally, we are looking to expand our laboratory operations and ramp up our production capacities. Ultimately, we want to enhance our contribution to global cancer treatment advancements while ensuring we meet regulatory standards and patient needs. Thank you for this opportunity to share my vision!
**Editor:** Thank you, Arnaud. We look forward to seeing the growth and innovations at Orano Med under your leadership.
